(S)-[5-AMINO-1-(4-METHOXY-PHENYLCARBAMOYL)-PENTYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER | 918433-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S)-[5-AMINO-1-(4-METHOXY-PHENYLCARBAMOYL)-PENTYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER
• 英文别名: (S)-[5-Amino-1-(4-methoxy-phenylcarbamoyl)-pentyl]-carbamic acid 9H-fluoren-9-ylmethyl ester；9H-fluoren-9-ylmethyl N-[(2S)-6-amino-1-(4-methoxyanilino)-1-oxohexan-2-yl]carbamate
• CAS: 918433-19-9
• 化学式: C₂₈H₃₁N₃O₄
• 分子量: 473.572
• InChiKey: MOWMDLVGQNTHOF-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-[5-AMINO-1-(4-METHOXY-PHENYLCARBAMOYL)-PENTYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER 、 大茴香酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 以147 mg的产率得到Fmoc-Lys-di-anisamide
  参考文献：
  名称：

  A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor

  摘要：

  Prostate cancer is a leading cause of cancer-related death in men and RNA interference (RNAi) has emerged as a potential therapeutic option. However, the absence of a safe and specific delivery vector remains a major obstacle to the clinical application of RNAi. Cyclodextrin derivatives are known to be efficient delivery systems with low toxicity in a variety of cell types. In this study, a cationic cyclodextrin derivative was synthesized to complex siRNA. The nanoparticle was then further modified by exploiting the ability of the beta-cyclodextrin cavity to form an inclusion complex with the hydrophobic molecule adamantane. PEGylated adamantane derivatives were synthesized with and without the anisamide-targeting ligand on the terminal end of the PEG chain. Anisamide is known to bind specifically to the sigma receptor which is overexpressed on the surface of prostate cancer cells. The resulting nanocomplexes were slightly cationic and less than 300 nm in size. They successfully protected siRNA from serum-induced nuclease degradation and were non-toxic to prostate cancer cells. In addition, the targeted nanoparticles mediated high levels of siRNA cellular uptake and corresponding PLK1 gene knockdown in prostate cancer cells in vitro. To our knowledge, this is the first time that the ability of cyclodextrins to form inclusion complexes with adamantane derivatives has been exploited for the targeted delivery of siRNA to prostate cancer cells via the sigma receptor. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ijpharm.2015.12.055
• 作为产物：
  描述：

  N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 在 盐酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 (S)-[5-AMINO-1-(4-METHOXY-PHENYLCARBAMOYL)-PENTYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER
  参考文献：
  名称：

  A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor

  摘要：

  Prostate cancer is a leading cause of cancer-related death in men and RNA interference (RNAi) has emerged as a potential therapeutic option. However, the absence of a safe and specific delivery vector remains a major obstacle to the clinical application of RNAi. Cyclodextrin derivatives are known to be efficient delivery systems with low toxicity in a variety of cell types. In this study, a cationic cyclodextrin derivative was synthesized to complex siRNA. The nanoparticle was then further modified by exploiting the ability of the beta-cyclodextrin cavity to form an inclusion complex with the hydrophobic molecule adamantane. PEGylated adamantane derivatives were synthesized with and without the anisamide-targeting ligand on the terminal end of the PEG chain. Anisamide is known to bind specifically to the sigma receptor which is overexpressed on the surface of prostate cancer cells. The resulting nanocomplexes were slightly cationic and less than 300 nm in size. They successfully protected siRNA from serum-induced nuclease degradation and were non-toxic to prostate cancer cells. In addition, the targeted nanoparticles mediated high levels of siRNA cellular uptake and corresponding PLK1 gene knockdown in prostate cancer cells in vitro. To our knowledge, this is the first time that the ability of cyclodextrins to form inclusion complexes with adamantane derivatives has been exploited for the targeted delivery of siRNA to prostate cancer cells via the sigma receptor. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ijpharm.2015.12.055

文献信息

• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供基于酰胺的非核苷化合物，具有对丙型肝炎病毒（HCV）等肝炎病毒的抗病毒活性，合成这些化合物的方法和中间体，以及在各种情况下使用这些化合物的方法，包括在治疗和预防病毒感染中。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源性聚合酶的抑制活性，例如聚合酶α和聚合酶γ。本公开进一步提供了用于治疗过度增殖疾病或障碍的用途，例如良性或恶性肿瘤，更具体地，是对聚合酶α和聚合酶γ抑制敏感的癌症。
• A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor
  作者：Kathleen A. Fitzgerald、Meenakshi Malhotra、Matt Gooding、Florence Sallas、James C. Evans、Raphael Darcy、Caitriona M. O’Driscoll

  DOI：10.1016/j.ijpharm.2015.12.055

  日期：2016.2

  Prostate cancer is a leading cause of cancer-related death in men and RNA interference (RNAi) has emerged as a potential therapeutic option. However, the absence of a safe and specific delivery vector remains a major obstacle to the clinical application of RNAi. Cyclodextrin derivatives are known to be efficient delivery systems with low toxicity in a variety of cell types. In this study, a cationic cyclodextrin derivative was synthesized to complex siRNA. The nanoparticle was then further modified by exploiting the ability of the beta-cyclodextrin cavity to form an inclusion complex with the hydrophobic molecule adamantane. PEGylated adamantane derivatives were synthesized with and without the anisamide-targeting ligand on the terminal end of the PEG chain. Anisamide is known to bind specifically to the sigma receptor which is overexpressed on the surface of prostate cancer cells. The resulting nanocomplexes were slightly cationic and less than 300 nm in size. They successfully protected siRNA from serum-induced nuclease degradation and were non-toxic to prostate cancer cells. In addition, the targeted nanoparticles mediated high levels of siRNA cellular uptake and corresponding PLK1 gene knockdown in prostate cancer cells in vitro. To our knowledge, this is the first time that the ability of cyclodextrins to form inclusion complexes with adamantane derivatives has been exploited for the targeted delivery of siRNA to prostate cancer cells via the sigma receptor. (C) 2015 Elsevier B.V. All rights reserved.